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2019 guidelines for the
diagnosis andmanagement
of chronic coronary
syndromes: congratulations
and criticism
The ESC released the new guidelines for the
diagnosis and management of chronic coron-
ary syndromes (CCS) in August 2019.1 On
November 14, a corrigendum was published
in the European Heart Journal2 following some
comments and suggestions.3,4
We would like to congratulate the authors
of the guidelines, particularly for the first part
related to symptoms and to the diagnostic
flowcharts. A new and more precise termin-
ology has been proposed [CCS instead of cor-
onary artery disease (CAD)] and, for the pre-
test probability model, a contemporary preva-
lence of CCS has been adopted, enriched by
the addition of several risk factors. For the first
time, dyspnoea is considered an ischaemic
equivalent. Congratulations for anticipating
the still unpublished suggestions of the
‘ISCHAEMIA’ trial and suggesting as the first
diagnostic test for CCS coronary computed
angiography (CTA) (to detect coronary anat-
omy) or non-invasive functional imaging (to
detect ischaemia) with a relative downgrading
of the ‘old’ exercise ECG. This, obviously,
is good for those who can afford CTA or
can perform a reliable non-invasive test.
Congratulations also for all the prevention
suggestions, in terms of lifestyle changes, re-
duction of progression of coronary athero-
sclerosis, and, in particular, prevention of
thrombus formation. For the latter, the guide-
lines consider in detail all of the different scen-
arios: whether patients are in sinus rhythm or
in atrial fibrillation or whether they have expe-
rienced a myocardial infarction or not, and
provide clear indications on how to use as-
pirin, antiplatelet therapies (and which one), as
well as the non-vitamin K antagonist oral anti-
coagulants and the concomitant use of proton
pump inhibitors.
The problems with these guidelines relate
to the approach to antianginal treatments.
The 2013 guidelines were severely criticized
for categorizing antianginal drugs in first- and
second-line treatment without supporting sci-
entific evidence.5–8 The criticism, unfortunate-
ly, remains for the 2019 guidelines. Despite
the test which states that there is no evidence
that one class of drugs is superior to another,
the flowchart continues to recommend a
stepwise strategy with first-, second-, even
third-, and, in some instances, fourth-line
drugs, and also contradicts the recommenda-
tions provided by the Regulatory Agencies
(EMA and FDA) which have generated the
publication of the corrigendum.2 It is not clear
how treatment with beta-blockers has the
highest level of labelling, 1A, in the absence of
multiple randomized trials (RCTs), while
other classes of drugs with more contempor-
ary and well-conducted RCTs are considered
only a third step. There is an inexplicable up-
grade for the use of long-lasting nitrates based
mainly on rather personal opinions in the ab-
sence of new supporting studies and evidence
that these drugs do not have any significant
additive antianginal effect.3,4 Taking into con-
sideration the multiplicity of mechanisms that
can cause myocardial ischaemia and CCS, and
in the absence of evidence that any drug is su-
perior to another, it would have been better,
as was done for the hypertension guidelines,9
to leave the choice of treatment to the practi-
tioners, according to the pathophysiology of
CCS or to patients’ comorbidities.
The recommendations for myocardial
revascularization of CCS are rather scanty and
basically the reader is referred to the 2018
ESC myocardial revascularization guidelines.10
However, even these are facing some
criticism as the European Association of
Cardio-Thoracic Surgery has withdrawn its
support as the guidelines recommended both
stents and heart surgery for low-risk patients,
largely based on the results of the EXCEL trial
which is raising concerns related to the defin-
ition of heart attack.11
Writing a guideline is a duty and a gift for a
few experts on behalf of the entire medical
community. It is not an easy job, particularly in
the absence of appropriate and contemporary
data. This generates a lot of congratulations
but also some criticism. Probably, for the 2019
guidelines on CCS, the congratulations will be
more than the criticism.
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